Hypertrophic neuropathy of Dejerine-Sottas

From WikiMD's WELLNESSPEDIA

Alternate names[edit]

Dejerine-Sottas syndrome; DSS; Charcot-Marie-Tooth Disease, type 3; CMT3; Hereditary motor and sensory neuropathy 3; HMSN3; Dejerine-Sottas neuropathy; DSN; Charcot-Marie-Tooth disease type 3; Hereditary motor and sensory neuropathy type 3; HMSN 3; Hypertrophic neuropathy of infancy; Hereditary motor and sensory neuropathy type III; HMSN III

Definition[edit]

Hypertrophic neuropathy of Dejerine-Sottas (Dejerine-Sottas syndrome) is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease (sometimes called type 3) that is characterized by sensory loss with ataxia in the limbs furthest from the body and pes cavus with progression towards the limbs closest to the body.

Types[edit]

Depending on the specific gene that is altered, this severe, early onset form of the disorder may also be classified as type 1 or type 4.

Cause[edit]

Dejerine-Sottas syndrome has been associated with mutations in the MPZ, PMP22, EGR2, and PRX genes.

Inheritance[edit]

Autosomal dominant and autosomal recessive inheritance have been described.

Signs and symptoms[edit]

It is characterized by sensory loss with ataxia in the limbs furthest from the body and pes cavus with progression towards the limbs closest to the body.

Diagnosis[edit]

  • On medical imaging, the nerves of the extremities (and cranial nerves in some cases) appear enlarged due to hypertrophy of the connective interstitial tissue, giving the nerves a distinct "onion-bulb" appearance.
  • Peripheral (and possibly cranial) nerve excitability and conduction speed are reduced.

Treatment[edit]

management is based on sign and symptoms.



NIH genetic and rare disease info[edit]

Hypertrophic neuropathy of Dejerine-Sottas is a rare disease.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.